150 related articles for article (PubMed ID: 19757300)
1. Limited prognostic value of the International Prognostic Score in advanced stage human immunodeficiency virus infection-related Hodgkin lymphoma treated with the doxorubicin, bleomycin, vinblastine, and dacarbazine regimen.
Xicoy B; Ribera JM; Miralles P; Berenguer J; Rubio R; Mahillo B; Valencia ME; Abella E; López-Guillermo A; Sureda A; Morgades M; Navarro JT; Esteban H
Leuk Lymphoma; 2009 Oct; 50(10):1718-20. PubMed ID: 19757300
[No Abstract] [Full Text] [Related]
2. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study.
Castillo JJ; Bower M; Brühlmann J; Novak U; Furrer H; Tanaka PY; Besson C; Montoto S; Cwynarski K; Abramson JS; Dalia S; Bibas M; Connors JM; Furman M; Nguyen ML; Cooley TP; Beltran BE; Collins JA; Vose JM; Xicoy B; Ribera JM;
Cancer; 2015 Feb; 121(3):423-31. PubMed ID: 25251326
[TBL] [Abstract][Full Text] [Related]
3. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma.
Xicoy B; Ribera JM; Miralles P; Berenguer J; Rubio R; Mahillo B; Valencia ME; Abella E; López-Guillermo A; Sureda A; Morgades M; Navarro JT; Esteban H; ;
Haematologica; 2007 Feb; 92(2):191-8. PubMed ID: 17296568
[TBL] [Abstract][Full Text] [Related]
4. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era.
Montoto S; Shaw K; Okosun J; Gandhi S; Fields P; Wilson A; Shanyinde M; Cwynarski K; Marcus R; de Vos J; Young AM; Tenant-Flowers M; Orkin C; Johnson M; Chilton D; Gribben JG; Bower M
J Clin Oncol; 2012 Nov; 30(33):4111-6. PubMed ID: 23045581
[TBL] [Abstract][Full Text] [Related]
5. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.
Hentrich M; Berger M; Wyen C; Siehl J; Rockstroh JK; Müller M; Fätkenheuer G; Seidel E; Nickelsen M; Wolf T; Rieke A; Schürmann D; Schmidmaier R; Planker M; Alt J; Mosthaf F; Engert A; Arasteh K; Hoffmann C
J Clin Oncol; 2012 Nov; 30(33):4117-23. PubMed ID: 23045592
[TBL] [Abstract][Full Text] [Related]
6. Hodgkin lymphoma among patients infected with HIV in post-HAART era.
Tanaka PY; Pessoa VP; Pracchia LF; Buccheri V; Chamone DA; Calore EE
Clin Lymphoma Myeloma; 2007 Mar; 7(5):364-8. PubMed ID: 17562247
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow up of patients with human immunodeficiency virus infection and advanced stage Hodgkin's lymphoma treated with doxorubicin, bleomycin, vinblastine and dacarbazine.
Xicoy B; Miralles P; Morgades M; Rubio R; Valencia ME; Ribera JM
Haematologica; 2013 Aug; 98(8):e85-6. PubMed ID: 23716563
[No Abstract] [Full Text] [Related]
8. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection.
Spina M; Gabarre J; Rossi G; Fasan M; Schiantarelli C; Nigra E; Mena M; Antinori A; Ammassari A; Talamini R; Vaccher E; di Gennaro G; Tirelli U
Blood; 2002 Sep; 100(6):1984-8. PubMed ID: 12200356
[TBL] [Abstract][Full Text] [Related]
9. Hodgkin's disease in HIV-infected patients: report of eight cases usefully treated with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) plus granulocyte colony- stimulating factor.
Gastaldi R; Martino P; Gentile G; Picardi V; De Propris MS; Pirillo MF; De Vellis A; Mandelli F
Ann Oncol; 2002 Jul; 13(7):1158-60. PubMed ID: 12176798
[No Abstract] [Full Text] [Related]
10. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
Jalali A; Ha FJ; Chong G; Grigg A; Mckendrick J; Schwarer AP; Doig R; Hamid A; Hawkes EA
Ann Hematol; 2016 Apr; 95(5):809-16. PubMed ID: 26878861
[TBL] [Abstract][Full Text] [Related]
11. Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma.
Ezzat HM; Cheung MC; Hicks LK; Boro J; Montaner JS; Lima VD; Harris M; Leitch HA
Leuk Lymphoma; 2012 Dec; 53(12):2390-6. PubMed ID: 22642935
[TBL] [Abstract][Full Text] [Related]
12. ABVD or BEACOPP
Fermé C; Thomas J; Brice P; Casasnovas O; Vranovsky A; Bologna S; Lugtenburg PJ; Bouabdallah R; Carde P; Sebban C; Eghbali H; Salles G; van Imhoff GW; Thyss A; Noordijk EM; Reman O; Lybeert MLM; Janvier M; Spina M; Audhuy B; Raemaekers JMM; Delarue R; Anglaret B; de Weerdt O; Marjanovic Z; Tersteeg RJHA; de Jong D; Brière J; Henry-Amar M; ;
Eur J Cancer; 2017 Aug; 81():45-55. PubMed ID: 28601705
[TBL] [Abstract][Full Text] [Related]
13. Stanford V regimen and concomitant highly active antiretroviral therapy is feasible and active in patients with Hodgkin's disease and HIV infection.
Spina M; Gabarre J; Fasan M; Vaccher E; Tirelli U
AIDS; 2000 Jul; 14(10):1457-8. PubMed ID: 10930165
[No Abstract] [Full Text] [Related]
14. Does Radiation Have a Role in Advanced Stage Hodgkin's or Non-Hodgkin Lymphoma?
Specht L
Curr Treat Options Oncol; 2016 Jan; 17(1):4. PubMed ID: 26739151
[TBL] [Abstract][Full Text] [Related]
15. Current status of the treatment of HIV-associated lymphoma.
Kaplan LD
Clin Adv Hematol Oncol; 2004 Jan; 2(1):28-9. PubMed ID: 16163156
[No Abstract] [Full Text] [Related]
16. Increased relapse rates in early stage hodgkin lymphoma (HL) patients without radiotherapy: the German Society of Radiooncology (DEGRO) advises to treat all early stage HL patients with radiotherapy.
Körholz D; Mauz-Körholz C; Vordermark D; Kluge R; Dieckmann K
Klin Padiatr; 2014 Nov; 226(6-7):307-8. PubMed ID: 25431863
[No Abstract] [Full Text] [Related]
17. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
Behringer K; Goergen H; Hitz F; Zijlstra JM; Greil R; Markova J; Sasse S; Fuchs M; Topp MS; Soekler M; Mathas S; Meissner J; Wilhelm M; Koch P; Lindemann HW; Schalk E; Semrau R; Kriz J; Vieler T; Bentz M; Lange E; Mahlberg R; Hassler A; Vogelhuber M; Hahn D; Mezger J; Krause SW; Skoetz N; Böll B; von Tresckow B; Diehl V; Hallek M; Borchmann P; Stein H; Eich H; Engert A; ; ;
Lancet; 2015 Apr; 385(9976):1418-27. PubMed ID: 25539730
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin, bleomycin, vinblastine, and dacarbazine alone in treatment of favorable, limited-stage Hodgkin's lymphoma: do we really have robust data?
Basaran G; Agaoglu F; Basaran M
J Clin Oncol; 2010 Sep; 28(27):e485-6; author reply e487. PubMed ID: 20606082
[No Abstract] [Full Text] [Related]
19. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M;
J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458
[TBL] [Abstract][Full Text] [Related]
20. Unusual manifestation of Hodgkin disease.
Dunlap N; Parkhie S
Am J Clin Oncol; 2006 Oct; 29(5):529-30. PubMed ID: 17023792
[No Abstract] [Full Text] [Related]
[Next] [New Search]